



[Reference Translation]

February 6, 2026

Company name: JMS Co., Ltd.
Name of representative: Ryuji Katsura, President and Representative Director
(Securities code: 7702; Tokyo Stock Exchange)
Inquiries: Yoshiki Ochiai, Executive Officer, Head of Corporate Affairs Division
(Telephone: +81-82-243-5844)

Notice of Revision of Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026.

Based on our initiatives for structural reforms outlined in Medium-term Management Plan 2027 and recent business performance trends, we hereby announce the revision of our consolidated earnings forecast for the fiscal year ending March 2026, which was announced on November 7, 2025, as follows:

1. Revision of Consolidated Earnings Forecast for the Fiscal Year Ending March 2026 (From April 1, 2025 to March 31, 2026)

(Unit: million yen)

| | Net sales | Operating profit | Ordinary profit | Profit attributable to owners of parent | Earnings per share |
|--|-----------|------------------|-----------------|---|--------------------|
| Forecast previously announced (A) | 66,000 | 500 | 300 | 100 | 4.08 yen |
| Forecast announced today (B) | 65,000 | 200 | 200 | (800) | (32.63) yen |
| Difference (B - A) | (1,000) | (300) | (100) | (900) | |
| Difference (%) | (1.5) | (60.0) | (33.3) | — | |
| <Reference> Actual results for previous fiscal year ended March 31, 2025 | 69,749 | 872 | 514 | 89 | 3.65 yen |

2. Reasons for the Difference and Revision

As part of structural reforms aimed at achieving optimal global production outlined in Medium-term Management Plan 2027, we are working on reorganizing production facilities, primarily overseas. Accordingly, we expect to incur costs of approximately 700 million yen (estimated amount) related to the disposal of fixed assets and inventories at our Korean production facility, and we plan to record extraordinary losses in the fiscal year ending March 2026.

Furthermore, with regard to net sales and profit for the third quarter consolidated cumulative period of the fiscal year ending March 2026, the impact of reduced orders for Apheresis Kits and Blood Bags due to inventory adjustments by major overseas customers continues. Although we are proceeding with price pass-through measures in response to inflation and streamlining unprofitable product lines, our performance is progressing at a pace below our previous forecast.

Taking these circumstances into consideration, we have revised our previous forecast for the full-year consolidated earnings forecast for the fiscal year ending March 2026, taking into account the results through the third quarter consolidated accounting period and the progress of structural reforms.

*The above earnings forecast is based on information currently available as of the date of this announcement and certain assumptions that we consider reasonable. Actual results may differ materially from these forecasts due to various factors.

END